Stihl's disease in an adult

B. A. Poleev

doi:10.17816/kazmj80697

Dynamics of indicators of reparative regeneration of the oral mucosa in patients with lichen planus

Periodontology ◽

10.33925/1683-3759-2019-24-3-264-268 ◽

2019 ◽

Vol 24 (3) ◽

pp. 264-268

Author(s):

I. V. Firsova ◽

S. V. Poroiskiy ◽

Yu. A. Makedonova ◽

Yu. M. Fedotova

Keyword(s):

Lichen Planus ◽

Oral Mucosa ◽

Laboratory Data ◽

Reparative Regeneration ◽

Layer By Layer ◽

Qualitative And Quantitative Analysis ◽

Cytological Examination ◽

Sandwich Technique ◽

Ulcerative Lesions ◽

Chronic Course

Relevance: red lichen planus refers to a long, protracted disease with a chronic course. There are a lot of root causes, it is quite diﬃcult to diﬀerentiate them. Therefore, pharmacotherapy of this pathology is reduced to the appointment of local drugs that have only symptomatic eﬀects that help accelerate the healing of the oral mucosa.Purpose – to study reparative regeneration based on the analysis of clinical and cytological examination on the background of the appointment of various methods of pharmacotherapy.Materials and methods: all patients were divided into two groups using simple randomization: in patients of the ﬁrst group, betamethasone B was used to treat erosive-ulcerative lesions, which were delivered to the lesion using Tisol, which has conductive transcutaneous activity, using the sandwich technique. The second group of patients used the drug delivery system in the form of a ﬁlm, which ﬁxed betamethasone B in the lesion area.Results: were evaluated before treatment, on day 7 and 14. The area and intensity of healing of the oral mucosa were determined, a qualitative and quantitative analysis of cytograms was carried out, which characterizes the dynamics of reparative regeneration of erosions and ulcers.Conclusion: based on the obtained clinical and laboratory data, it can be concluded that it is advisable to include betamethasone applications in the pharmacotherapy of patients with erosive and ulcerative forms of lichen planus. However, preference should be given to the method of layer-by-layer application of betamethasone B in combination with Tezol.

Download Full-text

Recent Advances in the Synthesis and Development of Nitroaromatics as Anti-Infective Drugs

Current Pharmaceutical Design ◽

10.2174/1381612826666200331091853 ◽

2020 ◽

Vol 26 (36) ◽

pp. 4658-4674 ◽

Cited By ~ 1

Author(s):

Christina Kannigadu ◽

David. D. N'Da

Keyword(s):

Infectious Disease ◽

Drug Resistance ◽

Chest Pain ◽

Muscle Pain ◽

New Drugs ◽

Lymph Glands ◽

Recent Advances ◽

Personality Changes ◽

Clinical Drugs ◽

Antiparasitic Agents

: Infectious diseases commonly occur in tropical and sub-tropical countries. The pathogens of such diseases are able to multiply in human hosts, warranting their continual survival. Infections that are commonplace include malaria, chagas, trypanosomiasis, giardiasis, amoebiasis, toxoplasmosis and leishmaniasis. Malaria is known to cause symptoms, such as high fever, chills, nausea and vomiting, whereas chagas disease causes enlarged lymph glands, muscle pain, swelling and chest pain. People suffering from African trypanosomiasis may experience severe headaches, irritability, extreme fatigue and swollen lymph nodes. As an infectious disease progresses, the human host may also experience personality changes and neurologic problems. If left untreated, most of these diseases can lead to death. : Parasites, microbes and bacteria are increasingly adapting and generating strains that are resistant to current clinical drugs. Drug resistance creates an urgency for the development of new drugs to treat these infections. Nitro containing drugs, such as chloramphenicol, metronidazole, tinidazole and secnidazole had been banned for use as antiparasitic agents due to their toxicity. However, recent discoveries of nitrocontaining anti-tuberculosis drugs, i.e. delamanid and pretonamid, and the repurposing of flexinidazole for use in combination with eflornithine for the treatment of human trypanosomiasis, have ignited interest in nitroaromatic scaffolds as viable sources of potential anti-infective agents. : This review highlights the differences between old and new nitration methodologies. It furthermore offers insights into recent advances in the development of nitroaromatics as anti-infective drugs.

Download Full-text

Medicinal importance of Papra (Podophyllum hexandrum Royle) in Unani System of Medicine

Journal of Complementary and Integrative Medicine ◽

10.1515/jcim-2020-0178 ◽

2021 ◽

Vol 0 (0) ◽

Author(s):

Mohd Afsahul Kalam ◽

Akhtar H. Malik ◽

Aijaz Hassan Ganie ◽

Tariq Ahmad Butt

Keyword(s):

Plant Species ◽

Podophyllum Hexandrum ◽

Kashmir Himalaya ◽

Unani Medicine ◽

Lymph Glands ◽

Pharmacological Studies ◽

Great Scholar ◽

Endemic Medicinal Plant ◽

Sinopodophyllum Hexandrum ◽

First Time

Abstract Podophyllum hexandrum Royle [=Sinopodophyllum hexandrum (Royle) T.S. Ying] is an important, endemic medicinal plant species of Himalaya. It is used in Unani System of Medicine under the name of ‘Papra’. The drug was not mentioned in previous literatures, but the first time it introduced in Unani Medicine by a great scholar Hakim Najmul Ghani. He has mentioned its uses and benefits in his classical book Khazainul Advia. In Unani Medicine the plant species has been used to treat various ailments like constipation, fever, jaundice, liver disorders, syphilis, diseases of lymph glands etc. In Kashmir Himalaya it is used to treat various diseases by local medicinemen, but now it is listed in rare drugs. Various pharmacological studies have been done such as antioxidant, antimicrobial, anti-inflammatory, antifungal, radio-protective etc., recently it has also been reported that podophyllotoxin or podophyllin can be used to treat some forms of cancers also.

Download Full-text

AB1046 JOINT MANIFESTATIONS IN A COHORT OF PATIENTS WITH SARCOIDOSIS IN A THIRD LEVEL HOSPITAL.

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2020-eular.6444 ◽

2020 ◽

Vol 79 (Suppl 1) ◽

pp. 1814.3-1814

Author(s):

I. Madroñal García ◽

C. Aguilera Cros ◽

L. Mendez Diaz

Keyword(s):

Medical Records ◽

Unknown Etiology ◽

Joint Involvement ◽

List Type ◽

Chi Square ◽

Exact Test ◽

Approximate Result ◽

Chronic Course ◽

Level Hospital ◽

Larger Sample

Background:Sarcoidosis (S) is a systemic granulomatous disease of unknown etiology, which most frequently affects the ganglion, lung and skin, although it can affect other organs, including the musculoskeletal system.Objectives:- Describe the clinical, analytical and radiological characteristics of patients diagnosed with S presenting joint manifestations.- To assess the association between patients who have joint manifestations and the use of corticosteroids (C) and immunosuppressants (IS), with respect to those without joint involvement.Methods:Retrospective descriptive study of patients with diagnosis of S with joint manifestations, treated in our Hospital from 2017 to 2019. Data were obtained by reviewing medical records. Chi square tests and Fisher’s exact test have been performed to establish the differences described in the objectives.Results:From a database of 102 patients with S, 18 presented joint manifestations (50% women), with a mean age of 57 ± 6 years. Of these patients, 4 (22.2%) have presented positive ANA. Regarding the clinic, 3 patients presented the association of polyarthritis and bilateral ankle swelling, 8 patients presented with polyarthritis, 3 monoatritis and 4 patients presented bilateral ankle swelling. 61.1% had fever at the onset of the disease.14 patients (77.8%) had high ACE values at the onset of the disease, without presenting significant differences with respect to all patients diagnosed with S who do not have joint involvement.All patients received treatment with C and 10 patients (55.5%) needed an IS treatment, finding no differences with respect to patients who do not have joint involvement (p=0.92).On the course of the disease, the majority of patients with joint involvement have a chronic course (72.2%). Nor were significant differences found when compared with patients who have no joint involvement (p = 0.73).Conclusion:Patients with joint involvement in our study have been 17.6% (18), an approximate result to that described in the literature (over 10%), although our result may be increased by the fact that the patients who are followed in Rheumatology present or have presented joint involvement. No significant differences were found between patients with S who presented joint involvement and those who did not, with respect to the initial ACE values, treatment and disease course. Prospective, multicenter and larger sample studies are necessary to better understand these associations.Disclosure of Interests:None declared

Download Full-text

TUBERCULOSIS OF THE INTERCOSTAL LYMPH GLANDS: LYMPHATIC DRAINAGE OF THE PLEURA

Journal of Thoracic Surgery ◽

10.1016/s0096-5588(20)32114-0 ◽

1938 ◽

Vol 8 (2) ◽

pp. 219-225

Author(s):

Willard Van Hazel

Keyword(s):

Lymphatic Drainage ◽

Lymph Glands

Download Full-text

AB1045 CLINICAL, ANALYTICAL AND RADIOLOGICAL CHARACTERISTICS OF A COHORT OF PATIENTS WITH SARCOIDOSIS.

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2020-eular.6414 ◽

2020 ◽

Vol 79 (Suppl 1) ◽

pp. 1814.2-1814

Author(s):

I. Madroñal García ◽

C. Aguilera Cros ◽

L. Mendez Diaz

Keyword(s):

Systemic Disease ◽

Immunosuppressive Treatment ◽

Clinical Manifestations ◽

Corticosteroid Treatment ◽

Pulmonary Involvement ◽

List Type ◽

Chi Square ◽

Course Of Disease ◽

Chronic Course ◽

Radiological Stage

Background:Sarcoidosis is a systemic disease whose etiology is unknown. It is characterized by the formation of granulomas in any tissue of the organism. Ganglionic, pulmonary and cutaneus involvement is the most prevalent.Objectives:Describe clinical characteristics of a cohort of patients with sarcoidosis diagnosed.Define the association between the ACE’s number at diagnosis, radiological lung stage, treatment and course of disease.Evaluate if the extrapulmonary involvement is related to the course of the disease.Methods:Descriptive retrospective study of patients with S diagnosis treated in our Hospital in 2019. Data were obtained by reviewing medical records. Chi-square tests and parametric tests have been used to establish the differences described in the objectives.Results:102 patients diagnosed with sarcoidosis have been included, (51% females) with an average age of 56±11 years. Suspected diagnosis at the onset of disease was S in 70.6% of patients, followed by suspected lymphoma (20.6%). The average time for the definitive diagnosis of S was 9.5 months. 70.6% of the patients had elevated ACE titles at the beginning. Regarding the clinical manifestations, 18.6% of the patients presented fever at the beginning and 66.7% extrathoracic clinical manifestations. 72.5% have lymph node adenopathies, and in 91% there is thoracic involvement (the most frequent pulmonary stage is stage II). A biopsy was performed in 84.3% of the patients, the lung biopsy being the most performed (52.3%). 88.2% of patients received corticosteroid treatment at the onset of the disease (currently under treatment with corticosteroids 37.3%). 50% of patients are treated with immunosuppressants, Methotrexate was the most used. 5 patients are treated with biological therapy (AntiTNF).Regarding the course of the disease, 51% of the patients have a chronic course, 45.1% are in remission and 3.9% have suffered a relapse of the disease. In this study, no significant relationship was found between the ACE values at the onset of the disease, the pulmonary stage and the course of the disease.According to our data, patients presenting with extrathoracic clinical manifestations need more frequently corticosteroid treatment (p = 0.017) and immunosuppressive treatment (p = 0.001) with respect to patients who do not have an extrathoracic clinic. In addition, patients with an extrathoracic clinic present more frequently a chronic course of the disease than those who do not (p = 0.019).Conclusion:The results described in this study are similar to those found in the literature. The differences found can be explained because patients presenting with extrathoracic clinical manifestations have a more complicated management and need more treatment than those with only pulmonary involvement, even patients with radiological stage I do not usually need treatment, only surveillance.Disclosure of Interests:None declared

Download Full-text

Ageing with psychosis – Fifty and beyond

Australian & New Zealand Journal of Psychiatry ◽

10.1177/00048674211009619 ◽

2021 ◽

pp. 000486742110096

Author(s):

Cherrie Galletly ◽

Shuichi Suetani ◽

Lisa Hahn ◽

Duncan McKellar ◽

David Castle

Keyword(s):

Negative Symptoms ◽

Psychotic Disorders ◽

Middle Age ◽

Treatment Strategies ◽

Population Based ◽

Course Of Illness ◽

Symptom Profile ◽

Chronic Course ◽

Current Emphasis ◽

Population Based Survey

Objective: While there is considerable current emphasis on youth and early psychosis, relatively little is known about the lives of people who live with psychotic disorders into middle age and beyond. We investigated social functioning, physical health status, substance use and psychiatric symptom profile in people with psychotic disorders aged between 50 and 65 years. Methods: Data were collected as part of the Survey of High Impact Psychosis, a population-based survey of Australians aged 18–65 years with a psychotic disorder. We compared those aged 50–65 years ( N = 347) with those aged 18–49 years ( N = 1478) across a range of measures. Results: The older group contained more women and more people with affective psychoses compared to the younger group. They were also more likely to have had a later onset and a chronic course of illness. The older group were more likely to have negative symptoms but less likely to exhibit positive symptoms; they also had lower current cognition, compared to the younger group. Compared to the younger group, the older group were more likely to be divorced/separated, to be living alone and to be unemployed. They had substantially lower lifetime use of alcohol and illicit substances, but rates of obesity, metabolic syndrome and diabetes mellitus were higher. Conclusion: Our findings suggest that the characteristics of people with psychosis change significantly as they progress into the middle age and beyond. A better understanding of these differences is important in informing targeted treatment strategies for older people living with psychosis.

Download Full-text